昆明理工大学学报(自然科学版)

参考文献

[1]Rosenberg B,Vancamp L.Platinum compounds:a new class of potent antitumour agents[J].Nature,1969,222:385-386.

[2]张伦.铂类抗癌药物市场分析[J].中国药房,2003,14(3):138-140.

[3]McKeage M J.Comparative adverse effect profiles of platinum drugs[J].Drug safety,1995,13(4):228-244.

[4]Weiss R B,Christian M C.New cisplatin analogues in development[J].Drugs,1993,46(3):360-377.

[5]Fuertes M A,Alonso C,Pérez J M.Biochemical modulation of cisplatin mechanisms of action:enhancement of antitumor activity and circumvention of drug resistance[J].Chemical Reviews,2003,103(3):645-662.

[6]Florea A M,Büsselberg D.Cisplatin as an anti-tumor drug:cellular mechanisms of activity,drug resistance and induced side effects[J].Cancers,2011,3(1):1351-1371.

[7]Rabik C A,Dolan M E.Molecular mechanisms of resistance and toxicity associated with platinating agents[J].Cancer treatment reviews,2007,33(1):9-23.

[8]Reedijk J.Improved understanding in platinium antitumour chemistry[J].Chem.Commun.,1996(7):801-806.

[9]Lebwohl D,Canetta R.Clinical development of platinum complexes in cancer therapy:an historical perspective and an update[J].European Journal of Cancer,1998,34(10):1522-1534.

[10]Ben-Bassat H,Vardi D V,Gazit A,et al.Tyrphostins suppress the growth of psoriatic keratinocytes[J].Experimental dermatology,1995,4(2):82-88.

[11]Bagrova S G.Results of phase II clinical trial of cycloplatam in refractory solid tumors[J].Voprosy onkologii,2000,47(6):752-756.

[12]Fuertes M A,Alonso C,Pérez J M.Biochemical modulation of cisplatin mechanisms of action:enhancement of antitumor activity and circumvention of drug resistance[J].Chemical Reviews,2003,103(3):645-662.

[13]Barnard C E J.The Chernistrv of the Platinum Metals[J].Platinum Metals Rev,1999,43(4):158-165.

[14]Todd R C,Lippard S J.Inhibition of transcription by platinum antitumor compounds[J].Metallomics,2009,1(4):280-291.

[15]Gibson D.The mechanism of action of platinum anticancer agents—what do we really know about it?[J].Dalton Transactions,2009(48):10681-10689.

[16]Siddik Z H.Cisplatin:mode of cytotoxic action and molecular basis of resistance[J].Oncogene,2003,22(47):7265-7279.

[17]Reedijk J.Increased understanding of platinum anticancer chemistry[J].Pure and Applied Chemistry,2011,83(9):1709-1719.

[18]Bernhard Lippert.Cisplatin[M].New York:John Wiley&Sons,1999.

[19]Hall M D,Okabe M,Shen D W,et al.The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy[J].Annu.Rev.Pharmacol.Toxicol.,2008,48:495-535.

[20]Liang X J,Shen D W,Chen K G,et al.Trafficking and localization of platinum complexes in cisplatin‐resistant cell lines monitored by fluorescence‐labeled platinum[J].Journal of cellular physiology,2005,202(3):635-641.

[21]Arnesano F,Natile G.Mechanistic insight into the cellular uptake and processing of cisplatin 30 years after its approval by FDA[J].Coordination Chemistry Reviews,2009,253(15):2070-2081.

[22]Safaei R,Howell S B.Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs[J].Critical reviews in oncology/hematology,2005,53(1):13-23.

[23]Lovejoy K S,Todd R C,Zhang S,et al.cis-Diammine(pyridine)chloroplatinum(II),a monofunctional platinum(II)antitumor agent:Uptake,structure,function,and prospects[J].Proceedings of the National Academy of Sciences,2008,105(26):8902-8907.

[24]Ishida S,Lee J,Thiele D J,et al.Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals[J].Proceedings of the National Academy of Sciences,2002,99(22):14298-14302.

[25]Landon C D,Benjamin S E,Ashcraft K A,et al.A role for the copper transporter Ctr1 in the synergistic interaction between hyperthermia and cisplatin treatment[J].International Journal of Hyperthermia,2013,29(6):528-538.

[26]Nakayama K,Kanzaki A,Terada K,et al.Prognostic value of the Cu-transporting ATPase in ovarian carcinoma patients receiving cisplatin-based chemotherapy[J].Clinical cancer research,2004,10(8):2804-2811.

[27]Samimi G,Katano K,Holzer A K,et al.Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B[J].Molecular pharmacology,2004,66(1):25-32.

[28]Ciarimboli G,Ludwig T,Lang D,et al.Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2[J].The American journal of pathology,2005,167(6):1477-1484.

[29]Oldfield S P,Hall M D,Platts J A.Calculation of lipophilicity of a large,diverse dataset of anticancer platinum complexes and the relation to cellular uptake[J].Journal of medicinal chemistry,2007,50(21):5227-5237.

[30]Davies M S,Berners-Price S J,Hambley T W.Rates of platination of AG and GA containing double-stranded oligonucleotides:Insights into why cisplatin binds to GG and AG but not GA sequences in DNA[J].Journal of the American Chemical Society,1998,120(44):11380-11390.

[31]Hall M D,Amjadi S,Zhang M,et al.The mechanism of action of platinum(IV)complexes in ovarian cancer cell lines[J].Journal of inorganic biochemistry,2004,98(10):1614-1624.

[32]Reedijk J.The mechanism of action of platinum anti-tumor drugs[J].Pure Appl Chem,1987,59(2):181-192.

[33]Reedijk J.Metal-ligand exchange kinetics in platinum and ruthenium complexes[J].Platinum Metals Review,2008,52(1):2-11.

[34]Eastman A.Characterization of the adducts produced in DNA by cis-diamminedichloroplatinum(II)and cis-dichloro(ethylenediamine)platinum(II)[J].Biochemistry,1983,22(16):3927-3933.

[35]Kartalou M,Essigmann J M.Recognition of cisplatin adducts by cellular proteins[J].Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis,2001,478(1):1-21.

[36]Zwelling L A,Anderson T,Kohn K W.DNA-protein and DNA interstrand cross-linking by cis-and trans-platinum(II)diamminedichloride in L1210 mouse leukemia cells and relation to cytotoxicity[J].Cancer research,1979,39(2 Part1):365-369.

[37]Woynarowski J M,Faivre S,Herzig M C S,et al.Oxaliplatin-induced damage of cellular DNA[J].Molecular pharmacology,2000,58(5):920-927.

[38]Jamieson E R,Lippard S J.Structure,recognition,and processing of cisplatin-DNA adducts[J].Chemical reviews,1999,99(9):2467-2498.

[39]Jung Y,Lippard S J.Direct cellular responses to platinum-induced DNA damage[J].Chemical reviews,2007,107(5):1387-1407.

[40]Desoize B,Madoulet C.Particular aspects of platinum compounds used at present in cancer treatment[J].Critical reviews in oncology/hematology,2002,42(3):317-325.

[41]Siddik Z H.Cisplatin:mode of cytotoxic action and molecular basis of resistance[J].Oncogene,2003,22(47):7265-7279.

[42]Gómez-Ruiz S,Maksimovic'-Ivanic'D,Mijatovic'S,et al.On the discovery,biological effects,and use of cisplatin and metallocenes in anticancer chemotherapy[J].Bioinorganic chemistry and applications,2012.

[43]Gonzalez V M,Fuertes M A,Alonso C,et al.Is cisplatin-induced cell death always produced by apoptosis?[J].Molecular pharmacology,2001,59(4):657-663.

[44]Lieberthal W,Triaca V,Levine J.Mechanisms of death induced by cisplatin in proximal tubular epithelial cells:apoptosis vs.necrosis[J].American Journal of Physiology-Renal Physiology,1996,270(4):F700-F708.

[45]Eguchi Y,Shimizu S,Tsujimoto Y.Intracellular ATP levels determine cell death fate by apoptosis or necrosis[J].Cancer research,1997,57(10):1835-1840.

[46]Zhou R,Vander Heiden M G,Rudin C M.Genotoxic exposure is associated with alterations in glucose uptake and metabolism[J].Cancer research,2002,62(12):3515-3520.

[47]Herceg Z,Wang Z Q.Failure of poly(ADP-ribose)polymerase cleavage by caspases leads to induction of necrosis and enhanced apoptosis[J].Molecular and cellular biology,1999,19(7):5124-5133.

[48]Hirsch T,Marchetti P,Susin S A,et al.The apoptosis-necrosis paradox.Apoptogenic proteases activated after mitochondrial permeability transition determine the mode of cell death[J].Oncogene,1997,15(13):1573-1581.

[49]Harhaji‐Trajkovic L,Vilimanovich U,Kravic‐Stevovic T,et al.AMPK‐mediated autophagy inhibits apoptosis in cisplatin‐treated tumour cells[J].Journal of cellular and molecular medicine,2009,13(9b):3644-3654.

[50]Shionogi.Nedaplatin[J].Drugs Fut,1993,18(11):1085.

[51]Debiopharm,Sanofi-Synthelabo,Reddy.Oxaliplatin[J].Pharma Project,2001,1:825-1837.

[52]Noji M,Okamoto K,Kidani Y,et al.Relation of conformation to antitumor activity of platinum(II)complexes of 1,2-cyclohexanediamine and 2-(aminomethyl)cyclohexylamine isomers against leukemia P388[J].Journal of medicinal chemistry,1981,24(5):508-515.

[53]Anon.Oxaliplatin-Eloxatin(R)-Oncolytic-Platinum complex[J].Drugs Fut,2000,25(6):644-645.

[54]Ikeda K,Okusaka T,Ikeda M,et al.Transcatheter arterial chemoembolization with a lipophilic platinum complex SM-11355(miriplatin hydrate)--safety and efficacy in combination with embolizing agents[J].Gan to kagaku ryoho.Cancer&chemotherapy,2010,37(2):271-275.

[55]Coley H M,Sarju J,Wagner G,et al.Synthesis and characterization of platinum(II)oxadiazoline complexes and their in vitro antitumor activity in platinum-sensitive and-resistant cancer cell lines[J].Journal of medicinal chemistry,2007,51(4):135-141.

[56]Gelmon K A,Vandenberg T A,Panasci L,et al.A phase II study of ZD0473 given as a short infusion every 3 weeks to patients with advanced or metastatic breast cancer:a National Cancer Institute of Canada Clinical Trials Group trial,IND 129[J].Annals of oncology,2003,14(4):543-548.

[57]Fokkema E,De Vries E G E,Meijer S,et al.Lack of nephrotoxicity of new oral platinum drug JM216 in lung cancer patients[J].Cancer chemotherapy and pharmacology,2000,45(1):89-92.

[58]Hensing T A,Hanna N H,Gillenwater H H,et al.Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer[J].Anti-Cancer Drugs,2006,17(6):697-704.